EdgeMarket › What Deep Track Capital, Lp reported owning
What Deep Track Capital, Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
6.1BPositions
63Quarter
2026-03-31Shown below
50largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| GH Guardant Health, Inc. | 308.4M | 5.0% | 3.3M | 170.69 | +191.8% |
| IMVT Immunovant, Inc. | 286.3M | 4.7% | 11.5M | 44.37 | +199.4% |
| TARS Tarsus Pharmaceuticals, Inc. | 252.5M | 4.1% | 3.6M | 72.70 | +31.2% |
| PCVX Vaxcyte, Inc. | 249.9M | 4.1% | 4.3M | 62.62 | +100.3% |
| GPCR Structure Therapeutics Inc. | 206.3M | 3.4% | 4.3M | 49.09 | +164.4% |
| AXSM Axsome Therapeutics, Inc. | 185.9M | 3.0% | 1.1M | 207.77 | +77.6% |
| unmapped CUSIP 03753U106 | 182.3M | 3.0% | 4.5M | — | — |
| OCUL OCULAR THERAPEUTIX, INC | 166.7M | 2.7% | 19.7M | 11.08 | -7.4% |
| VERA Vera Therapeutics, Inc. | 165.2M | 2.7% | 4.1M | 32.27 | +46.0% |
| ALMS ALUMIS INC. | 149.2M | 2.4% | 6.8M | 24.17 | +448.1% |
| IONS IONIS PHARMACEUTICALS INC | 146.4M | 2.4% | 1.9M | 59.74 | +39.5% |
| unmapped CUSIP 670703107 | 141.0M | 2.3% | 1.4M | — | — |
| ALKS Alkermes plc. | 127.0M | 2.1% | 3.6M | 48.33 | +66.8% |
| unmapped CUSIP 152309100 | 125.4M | 2.0% | 3.2M | — | — |
| MLTX MoonLake Immunotherapeutics | 119.5M | 2.0% | 6.4M | 15.76 | -70.9% |
| MAZE Maze Therapeutics, Inc. | 103.8M | 1.7% | 3.5M | 29.43 | +118.3% |
| ORKA Oruka Therapeutics, Inc. | 99.8M | 1.6% | 2.0M | 107.96 | +649.7% |
| NRIX Nurix Therapeutics, Inc. | 98.4M | 1.6% | 6.3M | 26.72 | +180.4% |
| GMAB GENMAB A/S | 98.3M | 1.6% | 3.7M | 33.45 | +39.0% |
| CYTK CYTOKINETICS INC | 90.6M | 1.5% | 1.4M | 76.84 | +105.9% |
| GRAL GRAIL, Inc. | 89.0M | 1.5% | 1.7M | 79.54 | +147.2% |
| LBRX LB PHARMACEUTICALS INC | 82.7M | 1.4% | 3.4M | 47.62 | — |
| MBX MBX Biosciences, Inc. | 82.3M | 1.3% | 2.8M | 66.33 | +386.6% |
| BCAX Bicara Therapeutics Inc. | 80.8M | 1.3% | 4.1M | 23.90 | +118.1% |
| CMPS COMPASS Pathways plc | 67.3M | 1.1% | 12.2M | 13.33 | +226.7% |
| BMRN BIOMARIN PHARMACEUTICAL INC | 65.0M | 1.1% | 1.1M | 66.70 | +15.1% |
| BBIO BridgeBio Pharma, Inc. | 62.5M | 1.0% | 841.4K | 81.50 | +66.7% |
| IMCR Immunocore Holdings plc | 58.2M | 1.0% | 1.9M | 36.88 | +13.5% |
| TNGX Tango Therapeutics, Inc. | 57.5M | 0.9% | 2.8M | 23.88 | +253.8% |
| DFTX Definium Therapeutics, Inc. | 56.7M | 0.9% | 3.0M | 44.91 | +375.2% |
| unmapped CUSIP 880881107 | 56.6M | 0.9% | 1.1M | — | — |
| GERN GERON CORP | 47.3M | 0.8% | 31.7M | 1.52 | +9.4% |
| ANIP ANI PHARMACEUTICALS INC | 46.1M | 0.8% | 600.0K | 75.35 | -16.9% |
| CRMD CorMedix Inc. | 42.6M | 0.7% | 6.3M | 8.20 | -39.3% |
| ATAI AtaiBeckley Inc. | 42.5M | 0.7% | 12.0M | 7.38 | +85.9% |
| CLDX Celldex Therapeutics, Inc. | 40.7M | 0.7% | 1.3M | 40.38 | +93.3% |
| COGT Cogent Biosciences, Inc. | 38.5M | 0.6% | 1.0M | 36.73 | +209.6% |
| CRVS Corvus Pharmaceuticals, Inc. | 36.5M | 0.6% | 2.5M | 14.46 | +178.6% |
| DYN Dyne Therapeutics, Inc. | 36.3M | 0.6% | 2.0M | 26.10 | +118.0% |
| unmapped CUSIP 834203309 | 36.1M | 0.6% | 1.1M | — | — |
| ACRS Aclaris Therapeutics, Inc. | 35.0M | 0.6% | 9.3M | 6.41 | +254.1% |
| MANE Veradermics, Inc | 31.6M | 0.5% | 500.0K | 102.82 | — |
| VSTM Verastem, Inc. | 30.4M | 0.5% | 5.7M | 6.89 | -17.2% |
| ENGN enGene Therapeutics Inc. | 29.8M | 0.5% | 4.4M | 1.78 | -53.9% |
| VRDN Viridian Therapeutics, Inc.\DE | 27.3M | 0.4% | 1.4M | 24.29 | +33.9% |
| XFOR X4 Pharmaceuticals, Inc | 26.2M | 0.4% | 6.3M | 4.04 | +44.3% |
| SLDB Solid Biosciences Inc. | 25.7M | 0.4% | 3.6M | 9.30 | +64.3% |
| ENTA ENANTA PHARMACEUTICALS INC | 24.7M | 0.4% | 2.0M | 13.47 | +52.7% |
| APGE Apogee Therapeutics, Inc. | 24.0M | 0.4% | 285.0K | 134.75 | +274.1% |
| KURA Kura Oncology, Inc. | 21.5M | 0.4% | 2.6M | 11.89 | +68.7% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →